At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 96 enrolled
Drug / intervention
secukinumab +1 moredrug
Likely dose
secukinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II, 24-week Study Investigating the Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy Refractory to Oral NSAIDs/Acetaminophen, Physiotherapy or Corticosteroid Injections
In Brief
A Phase 2 clinical trial evaluating secukinumab and Placebo for Tendinopathy. Completed, enrolled 96 participants across 12 sites in 5 countries.
Detailed Summary
This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTendinopathy
CountriesCzechia, Germany, Netherlands, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartDec 2017
Primary CompletionAug 2019
Study CompletionOct 2019
TodayJul 2026
First PostedNov 17, 2017
Enrollment StartDec 15, 2017
Primary CompletionAug 2, 2019
Study CompletionOct 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.6 years ago
Interventions
secukinumabdrug
AIN457 300 mg subcutaneously for 12 weeks
Placeboother
Placebo to match AIN457 subcutaneously for 12 weeks